Notice of Proposed Sale · 144
Replimune Group, Inc.
REPLNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Replimune Group Inc.
- Issuer CIK
- 0001737953
- SEC file number
- 001-38596
- Phone
- 7812229600
- Person for whose account securities are to be sold
- Kapil Dhingra
- Relationships to issuer
- Director
- Street
- 500 Unicorn Park Drive
- Street (continued)
- Suite 303
- City
- Woburn
- State / country code
- MA
- Postal code
- 01801
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 16,500 | 292,875 | 94,800,404 | 11/02/2026 | Nasdaq | J.P. Morgan Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- J.P. Morgan Securities LLC
- Street
- 270 Park Avenue
- Street (continued)
- 10th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10017
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 11/02/2026 | Stock Options | Issuer | 16,500 | N | 11/02/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 11/02/2026
- Signed
- /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Kapil Dhingra
Company context
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.